Appili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral Suspension
(RTTNews) - Biopharmaceutical company Appili Therapeutics, Inc. (APLI.TO, APLIF.PK) announced Monday that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC received approval from the U.S. Food and Drug Administration (FDA) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
ATI-1501, Appili's liquid oral reformulation of the antibiotic metronidazole, has been licensed to Saptalis for commercialization in the U.S., and other selected territories. The FDA also approved LIKMEZ as the brand name for ATI-1501.
Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the U.S. every year to help treat parasitic and anaerobic bacterial infections.
The current tablet form of metronidazole is the only other approved oral form on the U.S. market.
Appili expects to receive milestone payments and royalties from Saptalis based on this FDA approval and Saptalis' commercialization plans.
Rate Cut Hopes Drag The Dollar Down
Bay Street Likely To Open Slightly Higher, But Weak Metal Prices Could Weigh
FTSE 100 Up Marginally As Investors Look For Direction
CAC 40 Drifts Lower In Lackluster Trade
Sensex Jumps 746 Points As Focus Shifts To Trump-Putin Talks; Nifty Ends At 24,585
DAX Modestly Lower In Cautious Trade; Defense Stocks Drift Lower
UK Job Placements Decline Sharply On Weaker Confidence & Budget Pressures
